Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...

Investing.com -- Shares of Neurocrine (NASDAQ: NBIX) Biosciences (NASDAQ: NBIX) tumbled 11% as the company reported revenues that fell short of estimates. Despite reporting a 26% growth in INGREZZA® ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...

Q4 2024 Earnings Call Transcript February 6, 2025 Neurocrine Biosciences, Inc. misses on earnings expectations. Reported EPS ...

H.C. Wainwright lowered the firm’s price target on Neurocrine (NBIX) to $185 from $190 and keeps a Buy rating on the shares. FY25 Ingrezza ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/104.D7q0jHs_.js ...

Neurocrine Biosciences Inc (NBIX) reports robust sales growth and strategic investments amid competitive pressures and payer challenges.

CFO Matt Abernethy projected INGREZZA sales for 2025 to range between $2.5 billion and $2.6 billion, reflecting $250 million growth at the midpoint. He noted increased competitive pressure and payer ...

Neurocrine Biosciences, Inc.’s NBIX share price has dipped by 18.53%, which has investors questioning if this is right time ...

FY25 revenue consensus $2.79B.Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool ...

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.